Loading...
Loading...
INBX| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.5M |
| Gross Profit | -0.4M |
| Operating Expense | 161.0M |
| Operating I/L | -160.9M |
| Other Income/Expense | 2,018.9M |
| Interest Income | 2.7M |
| Pretax | 1,858.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 1,858.0M |
Inhibrx, Inc. is a clinical-stage biotechnology company specializing in the development of novel biologic therapeutic candidates. The company's pipeline includes INBRX-109, a Phase 2 clinical trial candidate for treating various cancers; INBRX-105, a Phase 1 clinical trial candidate for solid tumors; and INBRX-101, a Phase 1 clinical trial candidate for AAT deficiency treatment. Additionally, the company offers INBRX-106, an OX40 agonist for oncology indications. Inhibrx generates revenue through the development and potential commercialization of these therapeutic candidates, aiming to address unmet medical needs in the oncology and rare disease markets.
